Report : Asia-Pacific Hypertrophic and Keloid Scar Treatment Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Scar Type (Hypertrophic and Keloid), Product Type (Laser Products, Topical Products, Injectables, and Other Products), and End User (Hospitals, Clinics, and Homecare)
Injectables Segment to Dominate Asia-Pacific Hypertrophic and Keloid Scar Treatment Market during 2018–2027
According to a new market research study on “Asia-Pacific Hypertrophic and Keloid Scar Treatment Market to 2027 – COVID-19 Impact and Analysis and Forecast by Scar Type, Product Type, and End User,” is expected to reach US$ 2,455.28 million by 2027 from US$ 1,173.23 million in 2020. The market is estimated to grow at a CAGR of 11.1% from 2020 to 2027. The report provides trends prevailing in the Asia-Pacific hypertrophic and keloid scar treatment market along with the drivers and restraints pertaining to the market growth. Tapping market in emerging countries is the major factor driving the growth of the Asia-Pacific hypertrophic and keloid scar treatment market. However, unavailability of universal treatment due to high costs, side effects, and scanty awareness may hinder the growth of Asia-Pacific hypertrophic and keloid scar treatment market.
Asia-Pacific countries are expecting to witness a huge challenge due to the increasing prevalence of COVID-19. Due to the outbreak of disease, healthcare industries have been affected badly, considering the economic conditions in the current situation. Due to the increasing COVID-19 cases, the cost for many treatments has been lowered. Considering the economic operations and geographic condition, the outbreak of the disease has affected medical tourism, manufacturers of medical equipment, laser systems, accessories, and other problems posed by the shortage of healthcare infrastructure in Asia-Pacific low-income countries. After the first case in December 2019 in Wuhan, China, the COVID-19 has spread to at least 180 countries and regions. To prevent the spread of disease, restrictive measures have been taken in countries such as India, South Korea, Singapore, Malaysia, and the Philippines. According to the World Health Organization (WHO), due to the rapidly changing risk of COVID-19 affected countries and constantly controlling outbreak trends, any additional health measures are likely to interfere with international travel and trade significantly. Countries such as Japan and Australia are conducting virtual international conferences to anticipate the impact of COVID-19 on the cosmetic industry in the Asia Pacific. The ongoing COVID-19 pandemic has created a seismic shift in living and cosmetic habits in the region, and hypertrophic and keloid scar treatment has borne a significant brunt of this shopper shake-up. China is explicitly facing issues with the pandemic, leading to disruption of the supply chain and projected losses in revenue, marketing, and sales within all industries—especially the hypertrophic and keloid scar treatment—and the concerns of health within the production units and other public places.
The market for hypertrophic and keloid scar treatment market is segmented into scar type, product type, end user, and country. Based on scar type, the hypertrophic and keloid scar treatment market is segmented into hypertrophic and keloid. The hypertrophic segment held the largest share of the market in 2019. Based on product type, the hypertrophic and keloid scar treatment market is segmented into laser products, topical products, injectables, and other products. The injectables segment held the largest share of the market in 2019. Based on topical products, the market is segmented into gels, silicone sheets, creams, other. Based on laser, the market is segmented into CO2, pulse-dyed, other. Based on end user, the hypertrophic and keloid scar treatment market is segmented into hospitals, clinics, and homecare. The hospitals segment held the largest share of the market in 2019. Based on country, the market is segmented into the China, Japan, India, Australia, South Korea, and rest of Asia-Pacific. China held the largest share of the market in 2019.
Alliance Pharma PLC, Mölnlycke Health Care AB., Smith & Nephew, Newmedical Technology Inc., Lumenis, Sonoma Pharmaceuticals, Inc, Suneva Medical, HRA Pharma and Perrigo Company plc are among the leading companies in the Asia-Pacific hypertrophic and keloid scar treatment market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2019, Merz, a global leader in aesthetics and neurotoxins, and Laboratoire HRA Pharma SAS, a fast-growing, creative global consumer health business, today announced that they have signed an asset purchase agreement under which HRA Pharma will acquire global rights to the Mederma brand, including products across scar treatment, stretch marks and skincare categories.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com